New glucose monitor aims for pinpoint accuracy in diabetes care

NCT ID NCT07679347

First seen Jul 01, 2026 · Last updated Jul 01, 2026

Summary

This pilot study tests a new continuous glucose monitor (CGM) called SAVA in 20 adults with Type 1 Diabetes. Participants wear three SAVA sensors and one standard sensor for 15 days to check how well the SAVA measures blood sugar compared to lab tests. The study also looks at comfort and safety. Results will help decide if larger studies are worthwhile.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SAVA Continuous Glucose Monitor (device)

What this could lead to

If successful, this could lead to a more accurate and comfortable glucose monitor for people with Type 1 Diabetes.

What could go wrong

This is a small pilot study with only 20 participants, so results may not apply to everyone. The device may not meet accuracy targets or may cause discomfort.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.